Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
2021 · Nature Communications · 288 citations
https://doi.org/10.1038/s41467-021-26239-2
R
Rebecca E. O’Connor
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
90
Papers
3.2K
Citations
31
h-index
53
i10-index
Rebecca E. O’Connor is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Chromosomal and Genetic Variations & Genetic diversity and population structure & Genomics and Phylogenetic Studies. The author has an h-index of 31, co-authored 77 publications.
ORCID: 0000-0002-4270-970XPapers by this author
worksImpaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor
2018 · Nature Communications · 95 citations
https://doi.org/10.1038/s41467-017-02776-7
Fourth Report on Chicken Genes and Chromosomes 2022
2022 · Cytogenetic and Genome Research · 48 citations
https://doi.org/10.1159/000529376
An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism
2023 · Nature Communications · 30 citations
https://doi.org/10.1038/s41467-023-41646-3
Comparative Mapping of the Macrochromosomes of Eight Avian Species Provides Further Insight into Their Phylogenetic Relationships and Avian Karyotype Evolution
2021 · Cells · 25 citations
https://doi.org/10.3390/cells10020362
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist
2010 · BMC Pharmacology · 14 citations
https://doi.org/10.1186/1471-2210-10-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat